| [1] |
Cheng CK, Leung PC, et al. Molecular biology of gonadotropin-releasing hormone (GnRH)-Ⅰ，GnRH-Ⅱ，and their receptors in humans[J]. Endocr Rev, 2005, 26(2): 283-306.
|
| [2] |
Millar RP, Lu ZL, Pawson AJ, et al. Gonadotropin-releasing hormone receptors[J]. Endocr Rev, 2004, 25(2): 235-275.
|
| [3] |
Roch GJ, Rusby ER, Sherwood NM，et al. GnRH receptors and peptides: skating backward[J]. Gen Comp Endocrinol, 2014, 209: 118-134.
|
| [4] |
Cheung LW, Wong AS. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues[J]. FEBS J, 2008，275(22)：5479-5495.
|
| [5] |
Neill JD. GnRH and GnRH receptor genes in the human genome[J]. Endocrinology, 2002, 143(3)：737-743.
|
| [6] |
Lin LS, Roberts VJ, Yen SS. Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion[J]. J Clin Endocrinol Metab, 1995, 80(2)：580-585.
|
| [7] |
Peng C, Fan NC, Ligier M, et al. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells[J]. Endocrinology, 1994, 135(5): 1740-1746.
|
| [8] |
Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary[J]. Mol Cell Endocrinol, 1994, 106(1/2)：145-149.
|
| [9] |
Moriya T, Suzuki T, Pilichowska M, et al. Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma[J]. Pathol Int, 2001, 51(5)：333-337.
|
| [10] |
Pazaitou-Panayiotou K, Chemonidou C, Poupi A, et al. Gonadotropin-releasing hormone neuropeptides and receptor in human breast cancer: correlation to poor prognosis parameters[J]. Peptides, 2013, 42：15-24.
|
| [11] |
Grundker C, Emons G. The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis[J]. Front Endocrinol (Lausanne), 2017, 8: 187.
|
| [12] |
Baumann KH, Kiesel L, Kaufmann M, et al. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters[J]. Breast Cancer Res Treat，1993，25(1)：37-46.
|
| [13] |
Seitz S, Buchholz S, Schally AV, et al. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125[J]. BMC Cancer, 2014, 14: 847.
|
| [14] |
Buchholz S, Seitz S, Schally AV, et al. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition[J]. Int J Oncol, 2009, 35(4): 789-796.
|
| [15] |
Kottler ML, Starzec A, Carre MC, et al. The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer[J]. Int J Cancer, 1997, 71(4): 595-599.
|
| [16] |
Kim KY, Choi KC, Auersperg N, et al. Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway[J]. Endocr Relat Cancer, 2006, 13(1): 211-220.
|
| [17] |
Morgan K, Stewart AJ, Miller N, et al. Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo[J]. Cancer Res, 2008, 68(15): 6331-6340.
|
| [18] |
Fister S, Günthert AR, Aicher B, et al. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax[J]. Cancer Res, 2009, 69(16): 6473-6481.
|
| [19] |
Sperduti S, Limoncella S, Lazzaretti C, et al. GnRH antagonists produce differential modulation of the signaling pathways mediated by GnRH receptors[J]. Int J Mol Sci, 2019, 20(22): 5548.
|
| [20] |
Aguilar-Rojas A, Maya-Núñez G, Huerta-Reyes M, et al. Activation of human gonadotropin-releasing hormone receptor promotes down regulation of ARHGAP18 and regulates the cell invasion of MDA-MB-231 cells[J]. Mol Cell Endocrinol, 2018, 460: 94-103.
|
| [21] |
Aguilar-Rojas A, Huerta-Reyes M, Maya-Núñez G, et al. Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231[J]. BMC Cancer, 2012, 12: 550.
|
| [22] |
Gründker C, Bauerschmitz G, Schubert A, et al. Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH[J]. Int J Oncol, 2016, 48(6)：2713-2721.
|
| [23] |
Grundker C，Föst C, Fister S, et al. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo[J]. Breast Cancer Res, 2010, 12(4): R49.
|
| [24] |
Torrisi R, Bagnardi V, Rotmensz N, et al. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer[J]. Breast Cancer Res Treat, 2011, 126(2): 431-441.
|
| [25] |
Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer[J]. N Engl J Med, 2018, 379(2): 122-137.
|
| [26] |
Dellapasqua S, Gray KP, Munzone E, et al. Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial[J]. J Clin Oncol, 2019, 37(5): 386-395.
|
| [27] |
Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med, 2015, 372(10): 923-932.
|
| [28] |
Kim HJ, Yoon TI, Chae HD, et al. Concurrent gonadotropin-releasing hormone agonist administration with chemotherapy improves neoadjuvant chemotherapy responses in young premenopausal breast cancer patients[J]. J Breast Cancer, 2015, 18(4): 365-370.
|
| [29] |
Emons G, Sindermann H, Engel J, et al. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152[J]. Neuroendocrinology, 2009, 90(1): 15-18.
|
| [30] |
Emons G, Gorchev G, Harter P, et al. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5) [J]. Int J Gynecol Cancer, 2014, 24(2)：260-265.
|
| [31] |
Argyros O, Karampelas T, Asvos X, et al. Peptide-drug conjugate GnRH-sunitinib targets angiogenesis selectively at the site of action to inhibit tumor growth[J]. Cancer Res, 2016, 76(5): 1181-1192.
|
| [32] |
Kovács M, Vincze B, Horváth JE, et al. Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-Ⅲ analogs[J]. Peptides, 2007, 28(4): 821-829.
|
| [33] |
Ranđelović I, Schuster S, Kapuvári B, et al. Improved in vivo anti-tumor and anti-metastatic effect of GnRH-III-daunorubicin analogs on colorectal and breast carcinoma bearing mice[J]. Int J Mol Sci, 2019, 20(19): 4763.
|
| [34] |
Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2014, 15(8): 829-840.
|
| [35] |
Kim JW, Yadav DK, Kim SJ, et al. Anti-cancer effect of GV1001 for prostate cancer: function as a ligand of GnRHR[J]. Endocr Relat Cancer, 2019, 26(2): 147-162.
|